IP Library Granted Patent US 7,553,950
Granted Patent B2
US 7,553,950 · App. 11/638,178 · Granted Jun 30, 2009

Chondroitinase ABC I polynucleotides

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,553,950
App. No.
11/638,178
Granted
Jun 30, 2009
Kind
B2
Abstract

The invention relates to chondroitinase ABC I and uses thereof. In particular, the invention relates to recombinant and modified chondroitinase ABC I, their production and their uses. The chondroitinase ABC I enzymes of the invention are useful for a variety of purposes, including degrading and analyzing polysaccharides such as glycosaminoglycans (GAGs). These GAGs can include chondroitin sulfate, dermatan sulfate, unsulfated chondroitin and hyaluronan. The chondroitinase ABC I enzymes can also be used in therapeutic methods such as promoting nerve regeneration, promoting stroke recovery, treating spinal cord injury, treating epithelial disease, treating infections and treating cancer.

Claims (14)

1. An isolated nucleic acid that encodes a polypeptide comprising the amino acid sequence of SEQ ID NO:2.

2. The nucleic acid of claim 1 , wherein the nucleic acid sequence of the nucleic acid is as set forth in SEQ ID NO: 1.

3. A vector comprising the nucleic acid of claim 1 .

4. A vector comprising the nucleic acid of claim 2 .

5. A composition comprising the nucleic acid of claim 1 and a pharmaceutically acceptable carrier.

6. A composition comprising the nucleic acid of claim 2 and a pharmaceutically acceptable carrier.

7. A composition comprising the vector of claim 3 and a pharmaceutically acceptable carrier.

8. A composition comprising the vector of claim 4 and a pharmaceutically acceptable carrier.

9. A composition comprising the nucleic acid of claim 1 and a physiologically acceptable carrier.

10. A composition comprising the nucleic acid of claim 2 and a physiologically acceptable carrier.

11. A composition comprising the vector of claim 3 and a physiologically acceptable carrier.

12. A composition comprising the vector of claim 4 and a physiologically acceptable carrier.

13. An isolated nucleic acid that is a full-length complement of a nucleic acid encoding the polypeptide of SEQ ID NO: 2.

14. The isolated nucleic acid of claim 13 which is a full-length complement of the nucleic acid sequence of SEQ ID NO: 1.

Assignments (3)
CONFIRMATORY LICENSE Recorded Apr 5, 2011
From: MASSACHUSETTS INSTITUTE OF TECHNOLOGY
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 026073/0804 →
CHANGE OF NAME Recorded Jun 19, 2008
From: LG.PHILIPS LCD CO., LTD.
To: LG DISPLAY CO., LTD.
Reel/Frame 021147/0009 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 11, 2008
From: PRABHAKAR, VIKAS; CAPILA, ISHAN; RAMAN, RAHUL; BOSQUES, CARLOS; POJASEK, KEVIN; SASISEKHARAN, RAM
To: MASSACHUSETTS INSTITUTE OF TECHNOLOGY
Reel/Frame 020632/0368 →